keyword
MENU ▼
Read by QxMD icon Read
search

Copd treatment

keyword
https://www.readbyqxmd.com/read/29238184/determinants-of-exacerbation-risk-in-patients-with-copd-in-the-tiospir-study
#1
Peter Ma Calverley, Kay Tetzlaff, Daniel Dusser, Robert A Wise, Achim Mueller, Norbert Metzdorf, Antonio Anzueto
Background: Exacerbation history is used to grade the risk of COPD exacerbation, but its reliability and relationship to other risk factors and prior therapy is unclear. To examine these interrelationships, we conducted a post hoc analysis of patients in the TIOSPIR trial with ≥2 years' follow-up or who died on treatment. Patients and methods: Patients were grouped by their annual exacerbation rate on treatment into nonexacerbators, infrequent, and frequent exacerbators (annual exacerbation rates 0, ≤1, and >1, respectively), and baseline characteristics discriminating among the groups were determined...
2017: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29238182/adherence-to-a-copd-treatment-guideline-among-patients-in-hong-kong
#2
Ka Pang Chan, Fanny Ws Ko, Hok Sum Chan, Mo Lin Wong, Thomas Yw Mok, Kah Lin Choo, David Sc Hui
Background: This study aimed to assess the adherence rate of pharmacological treatment to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guideline published in 2011 and the prevalence of comorbidities among patients with COPD in Hong Kong (HK). Methods: Patients were recruited from five tertiary respiratory centers and followed up for 12 months. Data on baseline physiological, spirometric parameters, use of COPD medications and coexisting comorbidities were collected...
2017: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29237699/single-inhaler-triple-therapy-for-copd
#3
(no author information available yet)
The European Medicines Agency (EMA) has granted marketing authorisation for a pressurised metered dose inhaler (pMDI) containing beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium bromide (Trimbow - Chiesi Pharmaceuticals) for the treatment of chronic obstructive pulmonary disease (COPD) in patients not adequately treated with a combination of an inhaled corticosteroid (ICS) and a long-acting beta2 agonist (LABA).1-3 The manufacturer claims that this is a significant treatment advance for COPD patients, and that the use of one inhaler should simplify therapy and, therefore, may improve adherence...
December 2017: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29237441/potential-benefit-of-bosentan-therapy-in-borderline-or-less-severe-pulmonary-hypertension-secondary-to-idiopathic-pulmonary-fibrosis-an-interim-analysis-of-results-from-a-prospective-single-center-randomized-parallel-group-study
#4
Yosuke Tanaka, Mitsunori Hino, Akihiko Gemma
BACKGROUND: No drugs have been approved for the treatment of patients with pulmonary hypertension (PH) secondary to idiopathic pulmonary fibrosis (IPF), particularly those with idiopathic honeycomb lung. This study was conducted to investigate the long-term efficacy and safety of bosentan for PH based on changes in prognosis and respiratory failure. METHODS: IPF patients with borderline or less severe PH and completely organized honeycomb lung were randomized (1:1) to bosentan or no treatment for PH for 2 years and assessed at baseline and every 6 months for respiratory failure, activities of daily living (ADL), lung and heart functions by right cardiac catheterization, and other parameters...
December 13, 2017: BMC Pulmonary Medicine
https://www.readbyqxmd.com/read/29234369/bufei-yishen-granules-combined-with-acupoint-sticking-therapy-suppress-inflammation-in-chronic-obstructive-pulmonary-disease-rats-via-jnk-p38-signaling-pathway
#5
Yange Tian, Ya Li, Jiansheng Li, Suxiang Feng, Suyun Li, Jing Mao, Yang Xie, Xuefang Liu, Haoran Dong, Wanchun Zheng, Minghang Wang
The present study was initiated to explore the mechanism of the effects of Bufei Yishen granules combined with acupoint sticking therapy (Shu-Fei Tie) on inflammation regulated by c-Jun N-terminal kinase (JNK) and p38 MAPK signaling in COPD rats. Seventy-two rats were divided into healthy control (Control), Model, Bufei Yishen (BY), acupoint sticking (AS), Bufei Yishen + acupoint sticking (BY + AS), and aminophylline (APL) groups (n = 12 each). COPD rats were exposed to cigarette smoke and bacteria and were given the various treatments from weeks 9 through 20; all animals were sacrificed at the end of week 20...
2017: Evidence-based Complementary and Alternative Medicine: ECAM
https://www.readbyqxmd.com/read/29233650/impact-of-erdosteine-on-chronic-bronchitis-and-copd-a-meta-analysis
#6
Mario Cazzola, Luigino Calzetta, Clive Page, Paola Rogliani, Maria Gabriella Matera
A previous meta-analysis suggested that the treatment with erdosteine was associated with significant amelioration of the cumulative global efficacy index and symptoms in comparison to placebo or other mucolytics. However, this conclusion was criticized because the meta-analysis, as it had been done, made it impossible to preclude the potential operation of selection biases within and across trials, and identify any realised benefits of an individual patient data approach. Taking into consideration these criticisms and also the publication of two further recent articles focused on the prevention of chronic obstructive pulmonary disease (COPD) exacerbations with erdosteine, we have carried out a quantitative synthesis via meta-analysis of the currently available data on the use of this drug...
December 9, 2017: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29233103/anxiety-and-depression-among-patients-with-chronic-obstructive-pulmonary-disease-and-general-population-in-rural-nepal
#7
Niresh Thapa, Muna Maharjan, Tirtha Man Shrestha, Srijana Gauchan, Prakash Pun, Yam Bahadur Thapa
BACKGROUND: Anxiety and depression are usually under diagnosed among the patients with Chronic Obstructive Pulmonary Disease (COPD), which has a negative impact on patient quality of life through restriction of activities, loss of independence, and decreased social functioning. The purpose of this study was to describe the levels and characteristics of anxiety and depression in patients with COPD in Nepal as compared to the general population. METHODS: A hospital-based observational comparative analytical study was conducted in the United Mission Hospital, Tansen and the Okhaldhunga Community Hospital, Okhaldhunga, Nepal from June 1st 2015 to April 15th 2016...
December 12, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/29232988/does-antibiotic-treatment-duration-affect-the-outcomes-of-exacerbations-of-asthma-and-copd-a-systematic-review
#8
Marie Stolbrink, Jack Amiry, John D Blakey
Asthma and chronic obstructive pulmonary disease (COPD) cause significant morbidity and mortality worldwide, primarily through exacerbations. Exacerbations are often treated with antibiotics but their optimal course duration is uncertain. Reducing antibiotic duration may influence antimicrobial resistance but risks treatment failure. The objective of this article is to review published literature to investigate whether shorter antibiotic therapy duration affects clinical outcomes in the treatment of asthma and COPD exacerbations...
January 1, 2017: Chronic Respiratory Disease
https://www.readbyqxmd.com/read/29232680/is-outpatient-control-of-long-term-non-invasive-ventilation-feasible-in-chronic-obstructive-pulmonary-disease-patients
#9
Sarah Bettina Schwarz, Jens Callegari, Christine Hamm, Wolfram Windisch, Friederike Sophie Magnet
BACKGROUND: Long-term non-invasive ventilation (NIV) is an established and increasingly used treatment option for patients with chronic hypercapnic chronic obstructive pulmonary disease (COPD). Following inpatient NIV establishment, inpatient control visits regularly occur thereafter. However, it remains unclear whether such control visits can also be performed in an outpatient setting, which, in turn, would reduce costs, patient burden and the complications related to hospitalization...
December 12, 2017: Respiration; International Review of Thoracic Diseases
https://www.readbyqxmd.com/read/29231586/-effects-of-acupuncture-on-peripheral-skeletal-muscle-exercise-ability-in-patients-with-chronic-obstructive-pulmonary-disease-at-stable-phase
#10
Yan Ge, Hong Yao, Juan Tong, Ying He, Guiyuan Li, Xiang'ao Kong
OBJECTIVE: To explore the effects of acupuncture on improving the peripheral skeletal muscle exercise ability in patients with chronic obstructive pulmonary disease (COPD) at stable phase. METHODS: Forty-four patients were randomly divided into an observation group (24 cases) and a control group (20 cases). Based on regular western medication treatment and aerobic training, acupuncture was used in the observation group and placebo acupuncture was used in the control group...
April 12, 2017: Zhongguo Zhen Jiu, Chinese Acupuncture & Moxibustion
https://www.readbyqxmd.com/read/29231073/pelargonium-sidoides-preparation-eps-7630-in-copd-health-related-quality-of-life-and-other-patient-reported-outcomes-in-adults-receiving-add-on-therapy
#11
Heinrich Matthys, Petra Funk
OBJECTIVE: Patient-reported outcomes (PRO) such as health-related quality of life (HRQL) belong to the most important criteria for the evaluation of medical therapies in clinical trials or practice-based benefit assessments. We therefore revisited results of an earlier published clinical trial investigating the effects of the herbal drug preparation from the roots of Pelargonium sidoides EPs 7630, administered as add-on therapy in patients suffering from chronic obstructive pulmonary disease (COPD), with respect to HRQL and other PRO...
December 12, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29230274/factors-influencing-pharmacological-treatment-in-copd-a-comparison-of-2005-and-2014
#12
Josefin Sundh, Joakim Åberg, Mikael Hasselgren, Scott Montgomery, Björn Ställberg, Karin Lisspers, Christer Janson
Introduction: The aim was to investigate how the pattern of pharmacological treatment in Swedish patients with chronic obstructive pulmonary disease (COPD) has changed over a decade, and to identify factors associated with treatment. Methods: Data on patient characteristics and pharmacological treatment were collected using questionnaires from two separate cohorts of randomly selected primary and secondary care patients with a doctor's diagnosis of COPD in central Sweden, in 2005 (n = 1111) and 2014 (n = 1329)...
2017: European Clinical Respiratory Journal
https://www.readbyqxmd.com/read/29229109/evaluation-and-quantification-of-treatment-preferences-for-patients-with-asthma-or-copd-using-discrete-choice-experiment-surveys
#13
Henrik Svedsater, David Leather, Terry Robinson, Helen Doll, Beenish Nafees, Lisa Bradshaw
INTRODUCTION: To investigate treatment preferences of patients with asthma or chronic obstructive pulmonary disease (COPD), previously identified influential treatment factors were used to develop a discrete choice experiment (DCE) survey. METHODS: An internet-based survey was conducted with UK-resident adults (recruited using a commercial panel) who were currently receiving asthma/COPD treatment and had not taken part in the previous phase of this study (qualitative interviews to understand patient burden, life impact and treatment preferences)...
November 2017: Respiratory Medicine
https://www.readbyqxmd.com/read/29229103/effect-of-budesonide-formoterol-pressurized-metered-dose-inhaler-on-exacerbations-versus-formoterol-in-chronic-obstructive-pulmonary-disease-the-6-month-randomized-rise-revealing-the-impact-of-symbicort-in-reducing-exacerbations-in-copd-study
#14
Gary T Ferguson, Donald P Tashkin, Tor Skärby, Carin Jorup, Kristina Sandin, Michael Greenwood, Kristine Pemberton, Frank Trudo
BACKGROUND: Prevention of exacerbations is a primary goal for chronic obstructive pulmonary disease (COPD) therapy. This randomized, double-blind, double-dummy, parallel-group, multicenter study evaluated the effect of budesonide/formoterol pressurized metered-dose inhaler (pMDI) versus formoterol dry powder inhaler (DPI) on reducing COPD exacerbations. METHODS: 1219 patients aged ≥40 years with moderate-to-very-severe COPD (per lung function) and a history of ≥1 COPD exacerbation received budesonide/formoterol pMDI 320/9 μg twice daily (BID) during a 4-week run-in...
November 2017: Respiratory Medicine
https://www.readbyqxmd.com/read/29229085/prevalence-of-comorbidities-in-copd-patients-by-disease-severity-in-a-german-population
#15
Timm Greulich, Benjamin J D Weist, Andreas Rembert Koczulla, Sabina Janciauskiene, Andreas Klemmer, Wolfram Lux, Peter Alter, Claus F Vogelmeier
Chronic obstructive pulmonary disease (COPD) is commonly associated with multiple comorbidities. Our objective was to assess the prevalence of comorbidities in patients with COPD and to relate their prevalence to the severity of the disease by using a large German health care database. Based on the retrospective analysis of a two-year (2013-2014) database from the German Statutory Health Insurance system, we obtained a representative sample of 4,075,493 german insurants. This sample included 146,141 patients with COPD (age: ≥35 years)...
November 2017: Respiratory Medicine
https://www.readbyqxmd.com/read/29228950/indacaterol-glycopyrronium-is-cost-effective-compared-to-salmeterol-fluticasone-in-copd-flame-based-modelling-in-a-swedish-population
#16
Leif Bjermer, Job F M van Boven, Madlaina Costa-Scharplatz, Dorothy L Keininger, Florian S Gutzwiller, Karin Lisspers, Ronan Mahon, Petter Olsson, Nicolas Roche
BACKGROUND: This study assessed the cost-effectiveness of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) in chronic obstructive pulmonary disease (COPD) patients with moderate to very severe airflow limitation and ≥1 exacerbation in the preceding year. METHODS: A previously published and validated patient-level simulation model was adapted using clinical data from the FLAME trial and real-world cost data from the ARCTIC study. Costs (total monetary costs comprising drug, maintenance, exacerbation, and pneumonia costs) and health outcomes (life-years (LYs), quality-adjusted life-years (QALYs)) were projected over various time horizons (1, 5, 10 years, and lifetime) from the Swedish payer's perspective and were discounted at 3% annually...
December 11, 2017: Respiratory Research
https://www.readbyqxmd.com/read/29228947/estimating-prevalence-of-chronic-obstructive-pulmonary-disease-in-the-southern-cone-of-latin-america-how-different-spirometric-criteria-may-affect-disease-burden-and-health-policies
#17
Edgardo Sobrino, Vilma E Irazola, Laura Gutierrez, Chung-Shiuan Chen, Fernando Lanas, Matías Calandrelli, Jacqueline Ponzo, Nora Mores, Pamela Serón, Allison Lee, Jiang He, Adolfo L Rubinstein
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide. The study aimed to determine and compare the prevalence of COPD in the general population aged 45-74 years old according to fixed ratio and lower limit of normal (LLN) thresholds in four cities in the Southern Cone of Latin America. METHODS: The Pulmonary Risk in South America (PRISA) study used a 4-stage stratified sampling method to select 5814 participants from 4 cities in the Southern Cone of Latin America (Bariloche and Marcos Paz, Argentina; Temuco, Chile; and Pando-Barros Blancos, Uruguay)...
December 11, 2017: BMC Pulmonary Medicine
https://www.readbyqxmd.com/read/29228935/dosimetrically-administered-nebulized-morphine-for-breathlessness-in-very-severe-chronic-obstructive-pulmonary-disease-a-randomized-controlled-trial
#18
Piotr Janowiak, Małgorzata Krajnik, Zygmunt Podolec, Tomasz Bandurski, Iwona Damps-Konstańska, Piotr Sobański, David C Currow, Ewa Jassem
BACKGROUND: Systemic morphine has evidence to support its use for reducing breathlessness in patients with severe chronic obstructive pulmonary disease (COPD). The effectiveness of the nebulized route, however, has not yet been confirmed. Recent studies have shown that opioid receptors are localized within epithelium of human trachea and large bronchi, a target site for a dosimetric nebulizer. The aim of this study was to compare any clinical or statistical differences in breathlessness intensity between nebulized 2...
December 11, 2017: BMC Pulmonary Medicine
https://www.readbyqxmd.com/read/29228436/the-effect-of-ventilator-mask-atomization-inhalation-of-ipratropium-bromide-and-budesonide-suspension-liquid-in-the-treatment-of-copd-in-acute-exacerbation-period-on-circulating-levels-of-inflammation-and-prognosis
#19
D-H Jiang, X Wang, L-S Liu, D-D Ji, N Zhang
OBJECTIVE: We investigated the effects of ventilator mask atomization inhalation of ipratropium bromide and budesonide suspension liquid in the treatment of acute exacerbation COPD (AECOPD) on circulating levels of inflammatory factors and prognosis. PATIENTS AND METHODS: A total of 86 cases of patients on ventilator support were randomly divided into control group and observation group with 43 cases each. The control group was administered routine treatment including basic disease treatment, anti-infection, maintenance of a stable internal environment, nutritional support, oxygen inhalation and so on...
November 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29227727/a-randomized-clinical-trial-comparing-the-ellipta-and-handihaler-dry-powder-inhalers-in-patients-with-copd-inhaler-specific-attributes-and-overall-patient-preference
#20
Kathryn A Collison, Pinal Patel, Andrew F Preece, Richard H Stanford, Raj K Sharma, Gregory Feldman
This randomised, open-label, cross-over, placebo-containing inhaler study assessed patient preference indicators for ELLIPTA and HandiHaler dry powder inhalers in patients with COPD (NCT02786927; GSK identifier: 204983). The primary objective of this study was to assess patient preference between ELLIPTA and HandiHaler based on the number of steps needed to use the inhaler. Eligible patients ≥40 years of age with COPD were randomised 1:1 to receive their current COPD medication plus a placebo-containing ELLIPTA or HandiHaler inhaler once daily for 7 ± 2 days (treatment period 1); this was followed by a 7 ± 2-day placebo treatment with the alternative inhaler...
December 11, 2017: COPD
keyword
keyword
64161
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"